Patents by Inventor Dragutin Knezic

Dragutin Knezic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
    Patent number: 11951212
    Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: April 9, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
  • PEDIATRIC FORMULATIONS OF FERRIC CITRATE
    Publication number: 20240100011
    Abstract: Described herein are ferric citrate-containing pharmaceutical compositions (e.g., solid oral dosage forms such as tablets). The pharmaceutical compositions described here can be administered to a subject in need thereof. In particular, the pharmaceutical compositions described here can be administered to a subject who is ? about 18 years of age (e.g., about 6-18 years of age or about 12 to 17 years of age).
    Type: Application
    Filed: November 22, 2023
    Publication date: March 28, 2024
    Applicant: Keryx Biopharmaceuticals, Inc.
    Inventors: Dragutin KNEZIC, Aniruddh PATEL, Farzaneh SEYEDI, Anandhavalavan ARULMOZHI, Milind DIXIT
  • Pharmaceutical composition and administrations thereof
    Patent number: 11752106
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: September 12, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, Jr., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20220241206
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Application
    Filed: September 15, 2021
    Publication date: August 4, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni DOKOU, Shahla JAMZAD, John P. CAESAR, JR., Majed FAWAZ, Laura DAS, Chong-Hui GU, Patricia Nell HURTER, Meghna Jai ISRANI, Meghan M. JOHNSTON, Dragutin KNEZIC, Andrew G. KUZMISSION, HongRen WANG
  • Pharmaceutical composition and administrations thereof
    Patent number: 11147770
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: October 19, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, Jr., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, Hongren Wang
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES
    Publication number: 20210308053
    Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
    Type: Application
    Filed: March 17, 2021
    Publication date: October 7, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
  • Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
    Patent number: 10980746
    Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: April 20, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
  • A Pharmaceutical Composition Comprising An Oxazine Derivative And Its Use In The Treatment Or Prevention Of Alzheimer's Disease
    Publication number: 20190388428
    Abstract: The present invention relates to a pharmaceutical composition comprising an oxazine derivative BACE-1 inhibitor, a process for the preparation thereof, and its use in the treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: January 18, 2018
    Publication date: December 26, 2019
    Inventors: Miloud Achour, Brumo Galli, Edgar John, Michael Juhnke, Dragutin Knezic, Vishal Shamji Koradia, Rita Ramos
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20190274959
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 12, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni DOKOU, Shahla JAMZAD, John P. CAESAR, JR., Majed FAWAZ, Laura DAS, Chong-Hui GU, Patricia Nell HURTER, Meghna Jai ISRANI, Meghan M. JOHNSTON, Dragutin KNEZIC, Andrew G. KUZMISSION, HongRen WANG
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES
    Publication number: 20190125674
    Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
    Type: Application
    Filed: December 26, 2018
    Publication date: May 2, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
  • Pharmaceutical composition and administrations thereof
    Patent number: 10272046
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: April 30, 2019
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, Jr., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
  • Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
    Patent number: 10206877
    Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: February 19, 2019
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20170100340
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Application
    Filed: June 13, 2016
    Publication date: April 13, 2017
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni DOKOU, Shahla JAMZAD, John P. CAESAR, JR., Majed FAWAZ, Laura DAS, Chong-Hui GU, Patricia Nell HURTER, Meghna Jai ISRANI, Meghan M. JOHNSTON, Dragutin KNEZIC, Andrew G. KUZMISSION, HongRen WANG
  • PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES
    Publication number: 20150320736
    Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
    Type: Application
    Filed: April 14, 2015
    Publication date: November 12, 2015
    Inventors: Brian Dean Phenix, Laurent Jean-Claude Bagnol, Geoffrey Glen Brodeur, Sachin Chandran, Eleni Dokou, Lori Ann Ferris, Dragutin Knezic, Katie Lynn McCarty, Ales Medek, Sara A. Waggener
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20150246031
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Application
    Filed: May 19, 2015
    Publication date: September 3, 2015
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, JR., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai lsrani, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20150024047
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, JR., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20150010628
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders and mini-tablets and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Application
    Filed: May 30, 2014
    Publication date: January 8, 2015
    Inventors: Eleni Dokou, Shahla Jamzad, Laura Das, Meghna Jai Israni, Dragutin Knezic, Andrew G. Kuzmission
  • Pharmaceutical composition and administrations thereof
    Patent number: 8883206
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: November 11, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, Jr., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
  • PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
    Publication number: 20140255483
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Application
    Filed: May 23, 2014
    Publication date: September 11, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, JR., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
  • Co-crystals and pharmaceutical formulations comprising the same
    Patent number: 8541025
    Abstract: An immediate release formulation of an active ingredient.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: September 24, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni Dokou, Rahela Gasparac, Dragutin Knezic, Billie J. Kline, Valdas Jurkauskas